公开(公告)号：US20240208942A1

公开(公告)日：2024-06-27

申请号：US18280548

申请日：2022-03-14

申请人： CANWELL BIOTECH LIMITED

发明人： RONGLIANG LOU ,  NINGHUI YU

IPC分类号： C07D403/04 ,  A61K31/404 ,  A61K31/407 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4985 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

CPC分类号： C07D403/04 ,  A61K31/404 ,  A61K31/407 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4985 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

摘要： The invention provides novel inhibitors of methionine aminopeptidase 2 (MetAP-2) and pharmaceutical compositions thereof, and their use in and methods of treatment, reduction or prevention of certain diseases or conditions associated with MetAP-2 (e.g., cancer, obesity, rheumatoid arthritis and psoriasis).

公开(公告)号：US12016847B2

公开(公告)日：2024-06-25

申请号：US17653717

申请日：2022-03-07

申请人： Bristol-Myers Squibb Company

发明人： Martina Malatesta ,  Ellen Hope Filvaroff

IPC分类号： A61K31/437 ,  A61P35/00

CPC分类号： A61K31/437 ,  A61P35/00

摘要： The present application relates generally to methods for treating prostate cancer with substituted tricyclic derivative is 2-[3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof.

公开(公告)号：US20240199612A1

公开(公告)日：2024-06-20

申请号：US18550474

申请日：2022-03-16

申请人： SHIRE HUMAN GENETIC THERAPIES, INC.

发明人： Nikolaos PAPAIOANNOU ,  Jeremy Mark TRAVINS ,  Sarah Jocelyn FINK ,  John Mark ELLARD ,  Alastair RAE

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/506

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/506

摘要： The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

公开(公告)号：US20240199548A1

公开(公告)日：2024-06-20

申请号：US18283834

申请日：2022-03-25

申请人： Jacobio Pharmaceuticals Co., Ltd.

发明人： Yang YE ,  Xiuwei LI ,  Guiqun YANG ,  Fashun YAN ,  Yanping WANG ,  Wei LONG

IPC分类号： C07D209/44 ,  A61K31/4035 ,  A61K31/437 ,  A61K45/06 ,  C07D471/04

CPC分类号： C07D209/44 ,  A61K31/4035 ,  A61K31/437 ,  A61K45/06 ,  C07D471/04

摘要： Compounds of general Formula S-1, S-2, S-3 and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, compositions, and uses of such compounds.

公开(公告)号：US20240199535A1

公开(公告)日：2024-06-20

申请号：US18554365

申请日：2022-04-08

申请人： IMMUNIC AG

发明人： Christian GEGE ,  Hella KOHLHOF ,  Andreas MÜHLER ,  Daniel VITT

IPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

CPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

摘要： The invention relates to novel deuterated compounds of Formula (I)




and their use as medicaments.

公开(公告)号：US20240197666A1

公开(公告)日：2024-06-20

申请号：US18283787

申请日：2022-03-23

申请人： K-Gen Therapeutics, Inc.

发明人： Chun Jiang ,  Ruihong CHEN

IPC分类号： A61K31/22 ,  A61K31/122 ,  A61K31/222 ,  A61K31/223 ,  A61K31/23 ,  A61K31/232 ,  A61K31/336 ,  A61K31/397 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4409 ,  A61K39/395 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00 ,  A61K39/00

CPC分类号： A61K31/22 ,  A61K31/122 ,  A61K31/222 ,  A61K31/223 ,  A61K31/23 ,  A61K31/232 ,  A61K31/336 ,  A61K31/397 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4409 ,  A61K39/3955 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00 ,  A61K2039/505

摘要： This present disclosure relates to a method of stimulating an immune response using compounds that activate protein kinase C (PKC), including for treatment of a cancer, a precancerous lesion, a benign tumor, or a wound.

公开(公告)号：US20240189289A1

公开(公告)日：2024-06-13

申请号：US18278078

申请日：2022-03-04

申请人： The Brigham and Women`s Hospital, Inc.

发明人： Francisco J. Quintana ,  Kevin Julian Hodgetts ,  Veit Johannes Rothhammer ,  Cristina Gutierrez Vazquez

IPC分类号： A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/506 ,  A61P25/00

CPC分类号： A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/506 ,  A61P25/00

摘要： The present application provides EphB3 kinase inhibitors, useful intreating neurodegenerative or demyelinating diseases or conditions such as autoimmune encephalomyelitis and multiple sclerosis.

公开(公告)号：US20240182469A1

公开(公告)日：2024-06-06

申请号：US18488871

申请日：2023-10-17

申请人： Sanofi

发明人： Dirk Gretzke ,  Olaf Ritzeler ,  Uwe Heinelt ,  Volkmar Wehner ,  Friedemann Schmidt

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/02

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/02

摘要： The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

公开(公告)号：US20240173320A1

公开(公告)日：2024-05-30

申请号：US18466908

申请日：2023-09-14

申请人： Epizyme, Inc.

发明人： Kat COSMOPOULOS ,  Elayne Penebre

IPC分类号： A61K31/506 ,  A61K31/416 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/5513

CPC分类号： A61K31/506 ,  A61K31/416 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/5513 ,  A61K45/06

摘要： The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.

公开(公告)号：US11992490B2

公开(公告)日：2024-05-28

申请号：US17072093

申请日：2020-10-16

申请人： Incyte Corporation

发明人： Paul Smith ,  Jörg Wenzel

IPC分类号： A61K31/519 ,  A61K31/4155 ,  A61K31/437 ,  A61P17/00 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K31/519 ,  A61K31/4155 ,  A61K31/437 ,  A61P17/00 ,  A61K9/0014 ,  A61K9/0053 ,  A61K45/06

摘要： The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.